Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB, Jegede OA, Haas NB, Mcdermott DF, Bilen MA, Stein M, Sosman J, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Einstein D, Catalano PJ, Hammers H, Regan MM.
Atkins MB, et al. Among authors: peace dj.
J Immunother Cancer. 2024 Apr 11;12(4):e008293. doi: 10.1136/jitc-2023-008293.
J Immunother Cancer. 2024.
PMID: 38604810
Free PMC article.
Clinical Trial.